Specialized pro-resolving mediators (SPMs) are endogenous lipid mediators biosynthesized from omega-3 fatty acids (EPA, DHA) and arachidonic acid that actively orchestrate the resolution phase of inflammation. Unlike anti-inflammatory agents that merely suppress inflammatory signals, SPMs execute a distinct biological program: halting neutrophil infiltration, promoting efferocytosis (macrophage clearance of apoptotic cells), converting M1 macrophages to M2 macrophages, restoring barrier function, and downregulating pain pathways. The four SPM families—lipoxins, resolvins, maresins, and protectins—represent the molecular basis of active resolution of inflammation rather than passive decay.
Imagine a construction site after a major building project. The inflammatory phase is like the demolition crew: loud, destructive, necessary—they break down damaged structures, clear debris, and create controlled chaos. But if the demolition crew never leaves, you're left with permanent rubble and no new building. Standard anti-inflammatories (NSAIDs, steroids) are like turning off the demolition crew's power tools mid-job—the destruction stops, but nothing gets cleaned up or rebuilt.
SPMs are the professional cleanup and reconstruction team. They arrive with three specific job orders: (1) send the demolition crew home (stop neutrophil recruitment), (2) bring in specialized vacuum trucks to remove all debris—including dead cells—without a trace (efferocytosis via M2 macrophages), and (3) seal the perimeter fence (restore vascular and epithelial barriers). This team doesn't just stop inflammation; they actively complete it, leaving the site ready for tissue repair. But here's the critical constraint: this cleanup crew can only be deployed if you have the raw materials—omega-3 fatty acids are the fuel in their trucks. No EPA/DHA substrate means no SPMs, and the demolition site becomes a chronic wasteland of low-grade inflammation.
SPM biosynthesis occurs through the eicosanoid class switch—a metabolic shift from pro-inflammatory to pro-resolving lipid mediator production. The molecular cascade proceeds as follows:
Initiation Phase:
- Inflammatory stimuli (cytokines, LPS) upregulate COX-2 expression in inflammatory exudates
- Aspirin acetylates COX-2 at Ser-530, or inflammatory mediators S-nitrosylate COX-2 via iNOS-derived nitric oxide
- Modified COX-2 changes product specificity: instead of producing prostaglandin E2 (PGE2) from arachidonic acid, it generates 15R-HETE (hydroxyeicosatetraenoic acid)
SPM Family-Specific Pathways:
graph TD
A[Omega-3 Fatty Acids] --> B[DHA]
A --> C[EPA]
D[Omega-6] --> E[Arachidonic Acid]
B --> F[17-HpDHA]
B --> G[14-HpDHA]
C --> H[18-HEPE]
E --> I[15-epi-LXA4]
F -->|15-LOX| J[D-series Resolvins]
G -->|12-LOX| K[Maresins]
H -->|5-LOX| L[E-series Resolvins]
I -->|5-LOX| M[Lipoxins]
J --> N[RvD1-6]
K --> O[MaR1-2]
L --> P[RvE1-3]
M --> Q[LXA4, LXB4]
N --> R[Resolution Actions]
O --> R
P --> R
Q --> R
R --> S[Stop Neutrophil Infiltration]
R --> T[Promote Efferocytosis]
R --> U["M1→M2 Conversion"]
R --> V[Restore Barrier Function]
R --> W[Reduce Pain Signaling]
Receptor-Mediated Resolution Actions:
-
Resolvin D1 (RvD1) → binds ALX/FPR2 and GPR32 receptors on neutrophils and macrophages
- Neutrophils: blocks NF-kB activation → reduces CXCL1 secretion → halts further neutrophil recruitment
- Macrophages: activates Akt pathway → enhances phagocytic capacity → increases efferocytosis of apoptotic neutrophils by 40-60%
-
Resolvin E1 (RvE1) → binds ChemR23 (ERV1) and BLT1 receptors
-
Maresin 1 (MaR1) → binds LGR6 receptor on macrophages
- Promotes M2 polarization via PPARα activation
- Enhances wound healing through VEGF upregulation
- Reduces neuropathic pain via TRPV1 receptor desensitization in dorsal root ganglia
-
Lipoxin A4 (LXA4) → binds ALX/FPR2 receptor
- Stops PMN (polymorphonuclear neutrophil) transmigration across epithelium
- Stimulates non-phlogistic monocyte recruitment for tissue repair
- Restores epithelial barrier function by upregulating tight junction proteins (ZO-1, occludin)
Metabolic Inactivation:
- SPMs have short half-lives (minutes to hours) due to rapid enzymatic dehydrogenation by 15-prostaglandin dehydrogenase
- This ensures resolution is a time-limited, self-terminating process
- Chronic inflammation states show reduced SPM production and/or impaired SPM receptor expression
Critical Cofactors:
- 15-LOX and 5-LOX enzymes require adequate tissue oxygenation (hypoxia impairs SPM synthesis)
- Iron and selenium cofactors for lipoxygenase activity
- Adequate omega-3 tissue saturation: omega-3 index >8% enables optimal SPM production
SPMs represent a paradigm shift in inflammatory disease management—from suppression to active resolution. This distinction is central to cPNI's evolutionary perspective: acute inflammation is an adaptive response that must complete its full cycle, not be permanently interrupted.
Wound Healing Protocol Timing:
- Days 0-7 post-injury: Avoid omega-3 supplementation to allow full expression of inflammatory phase (neutrophil recruitment, pathogen clearance, damaged tissue removal)
- Days 7+: Begin DHA 2-4g daily to trigger SPM production and transition to proliferative phase
- Violating this timing (early omega-3 supplementation) can impair initial inflammatory cleanup; chronic omega-3 deficiency prevents resolution and causes persistent inflammation
Neuropathic Pain Management:
- DHA 6g/day increases resolvin D-series production → reduces neuropathic pain via:
- Clinical response typically emerges after 4-8 weeks (time required to saturate membrane phospholipids and upregulate SPM biosynthetic machinery)
- Mechanism: corrects the omega-6 to omega-3 ratio (typical Western diet 20:1, target <4:1)
NSAID Contraindication:
- NSAIDs block COX-2, preventing the acetylated-COX-2 that produces aspirin-triggered resolvins
- Regular NSAID use (>3 days) during acute injury extends inflammatory phase and delays healing by 30-50%
- Exception: Low-dose aspirin (75-100mg) acetylates COX-2 without completely inhibiting it, promoting aspirin-triggered lipoxin (ATL) and resolvin production
Chronic Inflammatory Conditions:
- Rheumatoid arthritis: Synovial fluid from RA patients shows 60-80% reduction in RvD1 and MaR1 compared to osteoarthritis controls
- Inflammatory bowel disease: Colonic biopsies show impaired lipoxin biosynthesis despite adequate COX-2 expression (enzyme present but not acetylated/nitrosylated)
- Asthma: Reduced SPM levels correlate with severity; RvE1 administration (experimental) reduces airway hyperresponsiveness
Metabolic Connections:
- SPM production requires metabolic flexibility: adequate mitochondrial beta-oxidation to generate acetyl-CoA for lipoxygenase activity
- Insulin resistance impairs SPM synthesis via mTORC1 hyperactivation (mTORC1 inhibits lipid class switching)
- Obesity shows chronic SPM deficiency despite adequate omega-3 intake due to adipose tissue sequestration of fatty acids
Selfish Immune System Application:
- In chronic stress states, the selfish immune system prioritizes immediate threat responses over long-term resolution
- Elevated cortisol suppresses 15-LOX expression → reduced SPM biosynthesis → incomplete resolution → low-grade inflammation
- This explains the transition from acute stress (adaptive) to chronic stress (maladaptive inflammation)
- Four SPM families derived from specific substrates: lipoxins (arachidonic acid), E-series resolvins (EPA), D-series resolvins (DHA), maresins (DHA), protectins (DHA)
- Lipoxin A4 halts neutrophil transmigration at EC50 = 0.1-1 nM (10-100x more potent than anti-inflammatory prostaglandins)
- RvD1 increases macrophage efferocytosis by 40-60% at concentrations of 1-10 nM
- RvE1 reduces PMN infiltration into inflamed tissues by 50-70% in experimental peritonitis models
- SPMs act via specific GPCRs: ALX/FPR2 (lipoxins, RvD1), ChemR23/ERV1 (RvE1), GPR32 (RvD1), LGR6 (MaR1)
- DHA at 6g/day achieves plasma levels sufficient for neuropathic pain reduction within 4-8 weeks
- Omega-3 index >8% (percentage of RBC membrane fatty acids as EPA+DHA) necessary for optimal SPM biosynthetic capacity
- SPM half-lives range from minutes to hours due to rapid dehydrogenase metabolism—ensuring resolution is time-limited
- Aspirin 75-100mg/day acetylates COX-2 to produce aspirin-triggered resolvins (ATL, AT-RvD1) without blocking prostaglandin synthesis
- NSAIDs block SPM production by inhibiting COX-2; ibuprofen >1200mg/day for >3 days delays wound healing by 30-50%
- First 7 days post-injury: avoid omega-3 to allow full inflammatory phase; after day 7, initiate omega-3 to trigger resolution
- SPM biosynthesis requires adequate tissue oxygenation—hypoxia impairs lipoxygenase enzyme activity
- Chronic inflammatory diseases show 60-80% reduction in synovial/tissue SPM levels compared to healthy controls
- Resolvins — D-series and E-series resolvins are the largest SPM family, with distinct receptor targets and tissue distributions
- Lipoxins — First SPMs discovered (1984); produced from arachidonic acid via sequential lipoxygenase actions
- Maresins — Macrophage-derived SPMs (MaR1, MaR2) that promote M2 polarization and tissue regeneration
- Protectins — Neuroprotective SPMs including protectin D1 (PD1), critical in resolving neuroinflammation
- Omega-3 fatty acids — Essential substrates; SPM production impossible without adequate EPA/DHA tissue saturation
- DHA — Primary substrate for D-series resolvins, maresins, and protectins; 6g/day therapeutic dose for neuropathic pain
- EPA — Substrate for E-series resolvins; typically dosed 2-3g/day for cardiovascular and inflammatory conditions
- Arachidonic acid — Omega-6 substrate for lipoxin biosynthesis; demonstrates pro-resolving capacity when properly metabolized
- Eicosanoid class switch — The metabolic pivot from prostaglandin/leukotriene synthesis to SPM production during resolution phase
- COX-2 — When acetylated (aspirin) or S-nitrosylated (iNOS), switches from PGE2 production to 15-epi-lipoxin synthesis
- COX-2 acetylation — Aspirin-mediated modification that enables aspirin-triggered lipoxin and resolvin biosynthesis
- COX-2 S-nitrosylation — Nitric oxide-mediated modification during inflammation that promotes SPM class switching
- 15-LOX — Key enzyme for D-series resolvin and protectin biosynthesis from DHA
- 5-LOX — Generates E-series resolvins from EPA and lipoxins from arachidonic acid; requires iron cofactor
- 12-LOX — Critical for maresin biosynthesis; converts DHA to 14S-HpDHA intermediate
- Efferocytosis — Macrophage clearance of apoptotic cells; increased 40-60% by RvD1 and MaR1 signaling
- M1 macrophages — Pro-inflammatory phenotype; SPMs trigger phenotypic switch to M2 via PPARγ and SOCS3 upregulation
- M2 macrophages — Pro-resolution phenotype promoted by SPMs; secrete VEGF, TGF-β for tissue repair
- Neutrophils — Primary target of SPM anti-recruitment actions; RvE1 blocks L-selectin-mediated endothelial adhesion
- Vascular permeability — SPMs restore barrier function by upregulating tight junction proteins and reducing VEGF secretion
- NSAIDs — Block COX-2 activity, preventing both prostaglandin production and SPM class switching; delay wound healing
- Aspirin — Unique NSAID that acetylates COX-2 to produce aspirin-triggered resolvins; low-dose (75-100mg) preserves pro-resolving activity
- Wound healing — SPMs orchestrate transition from inflammatory to proliferative phase; deficiency causes chronic non-healing wounds
- Neuropathic pain — RvD1, RvD2, and MaR1 reduce pain via TRPV1 desensitization and microglial deactivation
- Resolution of inflammation — SPMs are the molecular executors of active resolution, distinct from passive inflammatory decay
- Acute inflammatory response — SPMs do not block initial inflammation; they complete it by triggering the resolution program
- Chronic inflammation — Results from failed resolution due to SPM deficiency, impaired SPM receptor signaling, or metabolic dysfunction
- Low-grade inflammation — Persistent low-level cytokine production when resolution phase cannot fully execute
- Prostaglandin E2 — Pro-inflammatory eicosanoid produced by unmodified COX-2; class switching reduces PGE2 in favor of SPMs
- Leukotriene B4 — Pro-inflammatory lipid mediator; RvE1 antagonizes LTB4 signaling at BLT1 receptor
- Metabolic flexibility — Required for SPM biosynthesis; beta-oxidation generates acetyl-CoA for lipoxygenase cofactors
- Insulin resistance — Impairs SPM production via mTORC1 hyperactivation and disrupted lipid metabolism
- Obesity — Chronic SPM deficiency despite dietary omega-3 intake due to adipose sequestration and impaired enzyme expression
- Rheumatoid arthritis — Synovial fluid shows 60-80% SPM reduction; experimental SPM administration reduces joint inflammation
- Inflammatory bowel disease — Colonic SPM deficiency despite adequate COX-2 expression; failed lipid class switching
- Asthma — Reduced airway SPM levels correlate with severity; RvE1 reduces bronchial hyperresponsiveness
- Selfish immune system — Chronic stress prioritizes immediate immune responses over long-term resolution, suppressing SPM synthesis
- Cortisol — Elevated cortisol suppresses 15-LOX expression, reducing SPM biosynthetic capacity
- Nitric oxide — iNOS-derived NO S-nitrosylates COX-2, enabling SPM class switching during inflammation
- ALX-FPR2 receptor — GPCR for lipoxins and RvD1; mediates anti-neutrophil and pro-efferocytosis signaling
- TRPV1 — Pain receptor desensitized by maresin 1 in dorsal root ganglia, reducing neuropathic pain transmission
- Module 1 — Introduction to evolutionary medicine and cPNI principles
- Module 5 — Immunology and resolution pharmacology